ClinicalTrials.gg
CompletedNCT01997879Updated Aug 22, 2023

Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers

A Phase 1 interventional study of AR-13324 Ophthalmic Solution, 0.02% in Healthy, sponsored by Aerie Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-22.

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess systemic safety and absorption of AR-13324 in healthy volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

First submitted before Aerie Pharmaceuticals became part of Alcon.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male or female subjects at least 18 years of age.
  • Within 25% of their ideal weights.
  • Medically healthy subjects with clinically insignificant screening results (laboratory profiles, medical histories, ECGs, physical exam) as determined by the Investigator.
  • Non-tobacco/nicotine using subjects (minimum of 3 months non-tobacco/nicotine use prior to first dose).
  • Subjects with two normal (non-diseased) eyes, defined as nonclinically significant in the opinion of the investigator.
  • Intraocular pressure between 14 and 20 mm Hg (inclusive) in each eye at Screening/Qualification.
  • Best-corrected visual acuity (BCVA) in each eye of 20/40 or better.
  • Willing and able to provide written prior to any study related procedures and to comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  • Chronic or acute ophthalmic disease including glaucoma, macular degeneration, cataract (primary or secondary). Previous cataract surgery.
  • Known to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
  • Previous glaucoma intraocular surgery or glaucoma laser procedures.
  • Refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
  • Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months (e.g., laser treatment for glaucoma or retina).
  • Evidence of ocular infection, inflammation, cystoid macular edema, clinically significant blepharitis or conjunctivitis at (Screening/ Qualification), or a history of herpes simplex keratitis.
  • Ocular medication of any kind within 30 days of Screening/ Qualification
  • Any abnormality preventing reliable applanation tonometry of either eye.
  • Central corneal thickness greater than 600 µm.
  • Cannot demonstrate proper delivery of the eye drop.
  • Blood donations or blood loss, within the past 3 months, that would put the patient at risk with the multiple blood samples required in the present study.
  • Clinically significant abnormalities in laboratory tests at screening.
  • Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere with the study.
  • Participation in any study within the past 30 days prior to screening.
  • Changes of systemic medication that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
  • Due to status of preclinical safety program, women of who are pregnant, nursing, planning a pregnancy, or not using a physician-supervised form of for at least the last two months. An adult woman is considered to be of childbearing potential unless she is one year or three months post-surgical sterilization. All females of childbearing potential must have a negative urine or serum pregnancy test result at the screening examination and must not intend to become pregnant during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    AR-13324 Ophthalmic Solution, 0.02%

    Eyedrop

    Drug: AR-13324 Ophthalmic Solution, 0.02%

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Assessment

    Blood samples obtained to evaluate the systemic exposure (Area Under the Curve (AUC), Maximum Concentration, Time and half-life (Cmax, tmax and t ½)) to ocularly instilled AR-13324 and its metabolites as appropriate.

    Time frame: 8 Days

07

Study locations

1 site
  • Celerion
    Phoenix, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2013
First posted
Nov 28, 2013
Start
Nov 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Last update
Aug 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01997879
Responsible party
Sponsor
First posted
Nov 28, 2013
Start date
Nov 2013
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Aug 22, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion